You are viewing: China Immunoassay Market analysis
Part of: Immunoassay Market (Global)

The China Immunoassay Market was valued at $3123.55 Million in 2025 and projected to reach to $4619.54 Million by 2030, representing a compound annual growth rate of 8.1%. China's immunoassay market is positioned for exceptional growth through 2030, supported by substantial government healthcare investments and the expansion of diagnostic capabilities in both metropolitan and emerging markets.

China Immunoassay Market Trends and Insights

  • This accelerated expansion in China significantly outpaces the global immunoassay market CAGR of 6.1%, reflecting the country's strengthening healthcare infrastructure and rising diagnostic demand.
  • China's market growth is driven by increasing prevalence of chronic diseases, expanding healthcare accessibility in rural regions, and substantial government investment in diagnostic capabilities. The immunoassay sector in China benefits from rapid urbanization, growing middle-class populations seeking preventive healthcare, and technological advancement in point-of-care testing platforms.
  • China's regulatory environment has become increasingly supportive of in vitro diagnostic innovation, enabling faster market entry for both domestic and international manufacturers.
  • By 2030, China is expected to consolidate its position as a critical growth engine within the Asia Pacific immunoassay market, supported by rising laboratory automation adoption and increased clinical laboratory standardization across the country..

Key Market Statistics

  • CAGR (2025-2030) 8.1% CAGR
  • Market Size, 2025 ~USD 3123.55 Million
  • Forecast, 2030 ~USD 4619.54 Million
  • Country China

China Immunoassay Market Overview

Fastest Growing Market :

China's immunoassay market grows at 8.1% CAGR, significantly outpacing the global rate of 6.1%, driven by expanding healthcare infrastructure and increasing diagnostic demand across urban and rural regions.

Substantial Market Valuation :

The Chinese immunoassay market is valued at USD 3,123.55 million in 2025, with projections reaching USD 4,619.54 million by 2030, representing a USD 1.5 billion market expansion opportunity.

Healthcare Infrastructure Investment :

China's strengthening healthcare infrastructure, including hospital modernization and diagnostic center expansion, is creating robust demand for advanced immunoassay technologies and testing solutions.

Rising Diagnostic Demand :

Increasing prevalence of chronic diseases, aging population demographics, and government healthcare initiatives are driving accelerated adoption of immunoassay diagnostics across Chinese healthcare facilities.

China Immunoassay Market Dynamics

  • The country's aging population and rising incidence of chronic diseases are catalyzing demand for advanced diagnostic solutions.
  • Healthcare modernization initiatives and increased healthcare spending per capita are enabling hospitals and diagnostic centers to adopt cutting-edge immunoassay technologies.
  • This trajectory reflects China's transition toward preventive healthcare and early disease detection strategies. The competitive landscape in China is intensifying as both domestic manufacturers and international players establish stronger market presence.
  • Regulatory improvements and standardization of diagnostic protocols are facilitating market growth and technology adoption.
  • Strategic partnerships between Chinese healthcare institutions and diagnostic companies are accelerating innovation and market penetration.
  • By 2030, China is expected to represent a significant portion of Asia-Pacific immunoassay market value, driven by sustained economic growth and healthcare sector prioritization..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • China's immunoassay market will grow from USD 3,123.55M (2025) to USD 4,619.54M (2030) at 8.1% CAGR, outpacing global growth.
      • China's market expansion is driven by chronic disease prevalence, rural healthcare expansion, and government diagnostic investment.
      • Technological innovation in point-of-care testing and laboratory automation is accelerating immunoassay adoption across China.
      • China is positioned as the Asia Pacific region's primary growth driver for immunoassay diagnostics through 2030.

      Immunoassay Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment CLIA (Technology)
      Forecast Period 2025–2030
      Growth Rate CAGR of 6.1% from 2025 to 2030
      Largest Segment REAGENTS & KITS (Product)
      Market Size Base Year (Billions) ~USD 35.48 (2025)
      Revenue Forecast (Billions) ~USD 47.7 (2030)
      Segments Covered Product, Type, Purchase Mode, Technology, Specimen, Application

      China Immunoassay Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product

      • Analyzers
      • Reagents & Kits

      By Type

      • Clia Reagents & Kits
      • Closed-Ended Systems
      • Elisa Reagents & Kits
      • Elispot Reagents & Kits
      • Ifa Reagents & Kits
      • Open-Ended Systems
      • Other Reagents & Kits
      • Rapid Test Reagents & Kits
      • Western Blot Reagents & Kits

      By Purchase Mode

      • Outright Purchase
      • Rental Purchase

      By Technology

      • Clia
      • Elisa
      • Elispot
      • Ifa
      • Other Technologies
      • Rapid Tests
      • Western Blotting

      By Specimen

      • Blood
      • Other Specimens
      • Saliva
      • Urine

      By Application

      • Allergy Diagnostics
      • Autoimmune Disorders
      • Blood Screening
      • Bone & Mineral Disorders
      • Cardiology
      • Drug Monitoring & Testing
      • Endocrinology
      • Infectious Diseases
      • Newborn Screening
      • Oncology
      • Other Applications

      Target Audience

      • Diagnostic Equipment Manufacturers : Manufacturers need China-specific market data to assess market opportunity, plan production capacity, establish distribution networks, and develop localized product strategies for this high-growth market.
      • Healthcare Investment Firms : Investment professionals require detailed market sizing and growth projections for China to evaluate portfolio opportunities, identify acquisition targets, and assess return potential in the immunoassay sector.
      • Hospital & Diagnostic Center Operators : Healthcare facility managers need market insights to benchmark their immunoassay capabilities, identify technology upgrade opportunities, and plan capital investments aligned with market trends.
      • Pharmaceutical & Biotech Companies : Companies developing immunoassay-based products require China market intelligence to guide clinical trial planning, regulatory strategy, commercialization timelines, and market positioning decisions.
      • Healthcare Consultants & Analysts : Consulting professionals need comprehensive China market data to support client advisory work, competitive analysis, market entry strategies, and healthcare sector assessments.

      Key Companies in the China Immunoassay Market

      CompanyHQOwnershipStrongest segments
      PATHEON INCNetherlandsPrivate CompanyDrug Product Services (oral, sterile, packaging, lifecycle),Pharmaceutical Development Services (preclinical to clinical),Drug Substance Services (small-molecule and biologics APIs),
      ALERE INCUnited StatesPrivate CompanyInfectious disease diagnostics (rapid and serology, including ELISA and automated systems),Cardiometabolic and critical care point-of-care (blood gas, lipids, glucose, D-dimer, troponin, diabetes),Toxicology and workplace drug testing (devices, reagents, lab services, alcohol tests),
      FLUOR CORPORATIONUnited StatesPublic CompanyEnergy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining and metals, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, nuclear security, logistics, mission-critical O&M),
      CEPHEID INC.United StatesPrivate CompanyInfectious disease & healthcare-associated infection assays (Xpert on GeneXpert),Virology assays (including emergency use authorization tests),Oncology and genetics assays,
      IMMUCOR, INC.United StatesPrivate CompanyTransfusion (serology instruments and reagents, including NEO, Echo, Capture),Transplant & Molecular (HLA, HPA assays, Array Imaging System, BASIS, platelet-focused products),Other / Services and Ancillary Products,
      UNILABSSwitzerlandPrivate CompanyRoutine & Specialty Laboratory Testing,Medical Imaging,Pathology & Centres of Excellence (IVF, Fertility, Pregnancy, Targeted Diagnostics),
      EIKEN CHEMICAL CO., LTD.JapanPublic CompanyFecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and food/environmental microbiology,Urinalysis test strips and analyzers,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging,Diagnostics,Varian (Oncology),
      DANAHERUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (analytical instruments, genomics, and lab automation),Diagnostics (clinical instruments and consumables),
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      REVVITYUnited StatesPublic CompanyDiagnostics instruments and systems,Diagnostics reagents, assays, and consumables,Life science reagents and genomic workflow tools,
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology, Metabolic Disorders, Tumor Markers, Oncology,Molecular Diagnostics – Simplexa and Congenital CMV,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Tools,Other / Informatics & Software,
      QUIDELORTHO CORPORATIONUnited StatesPublic CompanyLabs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care,
      BIOMÉRIEUXFrancePublic CompanyClinical microbiology & AST (VITEK, CHROMID, ETEST, culture media, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassays & biomarkers (VIDAS, Hybiome CLIA),
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, immune response, oncology, sexual and reproductive health),Research PCR and enzymes (qPCR, digital PCR, RT-PCR, configured solutions),
      SYSMEX CORPORATIONJapanPublic CompanyHematology analyzers & reagents,Coagulation diagnostics,Urinalysis, blood gas, electrolyte,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.ChinaPublic CompanyPatient monitoring and life support (monitoring, ventilators, defibrillation, AED, anesthesia),Ultrasound and medical imaging (ultrasound, radiology, endoscope camera system),In-vitro diagnostics (CLIA, chemistry, hematology, laboratory diagnostics),

      PATHEON INC

      Patheon Inc. is a Netherlands-based pharmaceutical manufacturing company with 9,100 employees. Operating as a private company, it provides contract development and manufacturing services to the pharmaceutical industry.

      ALERE INC

      Alere Inc. is a United States-based diagnostics company founded in 1981 with 9,700 employees. Operating as a private company, it specializes in rapid diagnostic testing solutions for healthcare markets.

      FLUOR CORPORATION

      Fluor Corporation is a United States-based engineering and construction company founded in 1912 with 22,995 employees. As a public company, it provides design, engineering, procurement, and construction services across multiple industries.

      CEPHEID INC.

      Cepheid Inc. is a United States-based molecular diagnostics company founded in 1996 with 1,700 employees. Operating as a private company, it develops and manufactures automated molecular testing systems.

      IMMUCOR, INC.

      Immucor, Inc. is a United States-based immunohematology company founded in 1982 with 1,125 employees. As a private company, it specializes in blood bank and transfusion medicine diagnostic solutions.

      UNILABS

      Unilabs is a Switzerland-based clinical laboratory services company founded in 1987 with 1,897 employees. As a private company, it operates diagnostic laboratories across multiple European countries.

      EIKEN CHEMICAL CO., LTD.

      Eiken Chemical Co., Ltd. is a Japan-based diagnostics and pharmaceutical company founded in 1939 with 696 employees. As a public company, it manufactures in vitro diagnostic reagents and pharmaceutical products.

      ABBOTT

      Abbott is a United States-based healthcare company founded in 1888 with 115,000 employees. As a public company, it develops and manufactures diagnostics, medical devices, pharmaceuticals, and nutritional products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a Germany-based medical technology company founded in 1896 with 72,369 employees. As a public company, it manufactures and distributes diagnostic imaging, laboratory diagnostics, and point-of-care testing systems.

      DANAHER

      Danaher is a United States-based conglomerate founded in 1969 with 59,000 employees. As a public company, it operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based life sciences company founded in 1956 with 125,000 employees. As a public company, it provides laboratory equipment, reagents, and analytical instruments globally.

      REVVITY

      Revvity is a United States-based life sciences and diagnostics company founded in 1937 with 11,000 employees. As a public company, it manufactures and distributes analytical instruments and reagents for research and diagnostics.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is an Italy-based diagnostics company founded in 1968 with 3,242 employees. As a public company, it develops and manufactures in vitro diagnostic products for clinical laboratories.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a United States-based life sciences company founded in 1952 with 7,450 employees. As a public company, it manufactures and distributes reagents, instruments, and quality control products for clinical and research laboratories.

      QUIDELORTHO CORPORATION

      QuidelOrtho Corporation is a United States-based diagnostics company founded in 1979 with 6,500 employees. As a public company, it develops and manufactures rapid diagnostic tests and laboratory instruments.

      BIOMÉRIEUX

      bioMérieux is a France-based diagnostics company founded in 1963 with 14,894 employees. As a public company, it specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and clinical diagnostics.

      QIAGEN

      QIAGEN is a Netherlands-based molecular diagnostics company founded in 1984 with 5,500 employees. As a public company, it develops and manufactures sample preparation and molecular testing solutions.

      SYSMEX CORPORATION

      Sysmex Corporation is a Japan-based diagnostics company founded in 1968 with 10,861 employees. As a public company, it manufactures and distributes hematology, hemostasis, and clinical chemistry analyzers.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based life sciences and diagnostics company founded in 1999 with 18,000 employees. As a public company, it provides analytical instruments, software, and services for research and diagnostics.

      SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.

      Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is a China-based medical device company founded in 1991 with 21,288 employees. As a public company, it manufactures and distributes diagnostic imaging, patient monitoring, and laboratory instruments globally.

      Reasons to Buy this Report

      • Market Size & Growth Data : Access precise valuation figures for China's immunoassay market (USD 3,123.55M in 2025) with detailed 5-year forecasts, enabling accurate financial planning and investment decisions for market entry or expansion.
      • Competitive Intelligence : Understand China-specific market dynamics, competitive positioning, and player strategies to identify opportunities for differentiation and market share capture in this high-growth healthcare segment.
      • Regulatory & Infrastructure Insights : Gain comprehensive understanding of China's healthcare infrastructure development, regulatory environment, and government initiatives driving immunoassay adoption and market expansion.
      • Demand Driver Analysis : Identify key growth catalysts specific to China including aging demographics, chronic disease prevalence, and healthcare modernization trends to align product development and marketing strategies.
      • Strategic Planning Support : Leverage China-focused market intelligence for informed decision-making on partnerships, acquisitions, product launches, and resource allocation in this outpacing-global-growth market.

      Frequently asked questions

      What is the projected size of China's immunoassay market by 2030?

      China's immunoassay market is projected to reach USD 4,619.54 million by 2030, growing from USD 3,123.55 million in 2025.

      What is the CAGR for China's immunoassay market?

      China's immunoassay market is expected to grow at a compound annual growth rate of 8.1% between 2025 and 2030.

      How does China's immunoassay market growth compare to global trends?

      China's 8.1% CAGR significantly exceeds the global immunoassay market CAGR of 6.1%, positioning China as a high-growth region.

      What factors are driving growth in China's immunoassay market?

      Key drivers include rising chronic disease prevalence, expanding rural healthcare access, government diagnostic investment, urbanization, and technological advancement in point-of-care testing.

      What role does China play in the Asia Pacific immunoassay market?

      China is the primary growth engine for the Asia Pacific immunoassay market, driven by its large population, healthcare infrastructure development, and regulatory support for diagnostic innovation.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global immunoassay market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Health Canada, European Medicines Agency (EMA), and Centers for Disease Control and Prevention (CDC). These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives of major market companies, and industry consultants, to gather and verify critical qualitative and quantitative information and evaluate the market prospects. Several primary sources from both the supply and demand sides of the market were interviewed to collect qualitative and quantitative data. The following is a breakdown of the primary respondents:

      Immunoassay Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were employed to estimate and verify the total size of the immunoassay market. These methods were also widely used to determine the sizes of various subsegments within the market. The research methodology used to estimate the market size includes the following:

      Immunoassay Market

      Data Triangulation

      The total market was divided into several segments and subsegments after determining the overall market size from the estimation process. Where applicable, data triangulation and market breakdown techniques were used to complete the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both the demand and supply perspectives.

      Market Definition

      An immunoassay is a test that uses biochemistry to detect the presence or level of an analyte, which is a large protein or antibody produced in response to an infection. These assays are highly versatile and can be adapted to many formats based on user needs. Immunoassays have become popular and well-established procedures in laboratories. They rapidly and easily provide precise and accurate results. This technique is mainly used in clinical diagnostics, drug monitoring, drug discovery, and food testing.

      Stakeholders

      • Manufacturers and vendors of immunoassay instruments and consumables
      • Immunoassay product manufacturers
      • Diagnostic associations
      • Research associations involved in infectious and chronic disease research
      • Various research and consulting firms
      • Distributors of immunoassay instruments and consumables
      • Contract research manufacturers of immunoassays
      • Healthcare institutions
      • Clinical laboratories

      Report Objectives

      • To define, describe, and forecast the global immunoassay market by product, technology, specimen, application, end user, and region
      • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall immunoassay market
      • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa
      • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the immunoassay market.
      • To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the immunoassay market.

      Customization Options

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Portfolio Assessment

      • Product Matrix gives a detailed comparison of the product portfolios of the top five companies.

      Company Information

      • • Detailed analysis and profiling of additional market players (up to five).

      Geographical Analysis

      • A further breakdown of the Rest of European immunoassay market into countries
      • A further breakdown of the Rest of Asia Pacific immunoassay market into countries
      • A further breakdown of the Rest of Latin American immunoassay market into countries

      Get the Full Immunoassay Market Report

      Full forecast, segment splits, and company analysis for all Immunoassay Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status